Sagimet Biosciences Presents Clinical Denifanstat And Preclinical FASN Inhibitor Data At AASLD The Liver Meeting 2024
Sagimet Biosciences Presents Clinical Denifanstat And Preclinical FASN Inhibitor Data At AASLD The Liver Meeting 2024
SAN MATEO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the presentation of Phase 2b data demonstrating the anti-fibrotic activity of its fatty acid synthase (FASN) inhibitor denifanstat, and preclinical data demonstrating potential benefit of FASN inhibition in atherosclerosis, at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting 2024, November 15-19, 2024 in San Diego, California.Subset analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis in difficult-to-treat MASH patients
FASCINATE-2阶段2试验的子集分析表明，denifanstat改善了难治性脂肪肝肝炎患者的纤维化。
Both artificial intelligence (AI) and conventional pathology demonstrated denifanstat's strong anti-fibrotic activity
人工智能（AI）和传统病理学均显示，denifanstat具有强大的抗纤维化活性。
FASN inhibitor treatment reduced atherosclerosis development in mouse model of dyslipidemia and MASH
FASN抑制剂治疗降低了鼠模型中脂质代谢紊乱和MASH的动脉粥样硬化发展。
SAN MATEO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the presentation of Phase 2b data demonstrating the anti-fibrotic activity of its fatty acid synthase (FASN) inhibitor denifanstat, and preclinical data demonstrating potential benefit of FASN inhibition in atherosclerosis, at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting 2024, November 15-19, 2024 in San Diego, California.
加州圣马特奥，2024年11月18日（环球新闻社）-- 世纪生物科学公司（Sagimet, 纳斯达克:SGMT）是一家处于临床阶段的生物制药公司，正在开发针对代谢和纤维化病路的新颖治疗药物，今天宣布在美国肝病研究协会（AASLD）2024年度会议 - 肝病大会上，于2024年11月15日至19日在加州圣迭戈举行，展示了FASN抑制剂denifanstat的第20亿期数据，表明其抗纤维化活性，并展示了FASN抑制在动脉粥样硬化中的潜在益处。
